67 Lymphoma Clinical Trials in New York, NY (2026)

Q: How do I join a clinical trial in New York?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you.

Recruiting Lymphoma Studies in New York

NCT04685616Recruiting

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) an...

New York, NYPHASE31,042 participantsUniversity College, London

View Study Details

NCT06091254Recruiting

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin...

New York, NYPHASE3822 participantsRegeneron Pharmaceuticals

View Study Details

NCT00582621Recruiting

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

The purpose of this study is to better understand the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. ...

New York, NY500 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06090539Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrad...

New York, NYPHASE1460 participantsBristol-Myers Squibb

View Study Details

NCT06564038Recruiting

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

The purpose of this study is to assess the safety and efficacy of AZD0486 administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies....

New York, NYPHASE1408 participantsAstraZeneca

View Study Details

NCT02840747Recruiting

Tissue Repository: CTCL Collection Protocol

This document is a protocol for a non-interventional human research study in which the investigator hopes to better understand the changes that take place in T cells in Cutaneous T-cell lymphoma (CTCL...

New York, NY400 participantsColumbia University

View Study Details

NCT07029217Recruiting

A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas

The researchers are doing this study to find out whether a very low dose of radiation therapy (VLDRT) is an effective treatment for people with follicular lymphoma (FL) or marginal zone lymphoma (MZL)...

New York, NYPHASE3375 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05091424Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic...

New York, NYPHASE1332 participantsHoffmann-La Roche

View Study Details

NCT05700149Recruiting

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

International retrospective observational cohort study aimed to describe a molecular classification for NMZL....

New York, NY300 participantsInternational Extranodal Lymphoma Study Group (IELSG)

View Study Details

NCT04104776Recruiting

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid ...

New York, NYPHASE1275 participantsNovartis Pharmaceuticals

View Study Details

NCT03618550Recruiting

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma....

New York, NYPHASE2257 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06393738Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R...

New York, NYPHASE1255 participantsArvinas Inc.

View Study Details

NCT04989803Recruiting

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma....

New York, NYPHASE1247 participantsKite, A Gilead Company

View Study Details

NCT04970901Recruiting

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the ...

New York, NYPHASE1200 participantsADC Therapeutics S.A.

View Study Details

NCT07082803Recruiting

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies i...

New York, NYPHASE1180 participantsTreeline Biosciences, Inc.

View Study Details

NCT05463263Recruiting

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas....

New York, NYPHASE1180 participantsStep Pharma, SAS

View Study Details

NCT06542250Recruiting

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Ma...

New York, NYPHASE1174 participantsAstraZeneca

View Study Details

NCT06137144Recruiting

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.

This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in p...

New York, NYPHASE1161 participantsAstraZeneca

View Study Details

NCT05512390Recruiting

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma....

New York, NYPHASE1154 participantsAbbVie

View Study Details

NCT04300998Recruiting

Study of CAR-T Therapy in Older Patients

This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life. This is a quality of life study and participating in the stud...

New York, NY154 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05389293Recruiting

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their di...

New York, NYPHASE2152 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07691606Recruiting

A Study of ARC-02 in B-cell NHL

This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02....

New York, NYPHASE1140 participantsTaiho Oncology, Inc.

View Study Details

NCT03666000Recruiting

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T,...

New York, NYPHASE1135 participantsImugene Limited

View Study Details

NCT06745076Recruiting

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

This phase II trial tests how well personalized reduction of chemotherapy (nivolumab, doxorubicin, vinblastine and dacarbazine) based on circulating tumor deoxyribonucleic acid (ctDNA) evaluation work...

New York, NYPHASE2125 participantsUniversity of Washington

View Study Details

NCT06238648Recruiting

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chi...

New York, NYPHASE2120 participantsAcademic and Community Cancer Research United

View Study Details

NCT04107285Recruiting

Looking at Cognitive and Brain Changes in People With Lymphoma Receiving CAR-T Therapy

The purpose of this study is to learn about possible changes in cognitive (mental) abilities, such as memory skills and concentration, and in brain anatomy (structure) and function, in people with lym...

New York, NY120 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05685173Recruiting

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with relapsed or refractory aggressive B-cell Non-...

New York, NYPHASE1107 participantsRegeneron Pharmaceuticals

View Study Details

NCT05783609Recruiting

Epcoritamab and Rituximab for First-line Follicular Lymphoma

The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other trea...

New York, NYPHASE2100 participantsReid Merryman, MD

View Study Details

NCT06098430Recruiting

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

There is a pressing need to measure patient-reported symptoms in patients of all ages diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). This study aims to measure longitudinal sy...

New York, NY100 participantsSt. Jude Children's Research Hospital

View Study Details

NCT06712459Recruiting

Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma

Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the ...

New York, NY100 participantsInternational Extranodal Lymphoma Study Group (IELSG)

View Study Details

NCT07123454Recruiting

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Ref...

New York, NYPHASE191 participantsAstraZeneca

View Study Details

NCT02974647Recruiting

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT...

New York, NYPHASE283 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06634589Recruiting

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed...

New York, NYPHASE180 participantsBeiGene

View Study Details

NCT05798897Recruiting

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starti...

New York, NYPHASE179 participantsMarker Therapeutics, Inc.

View Study Details

NCT05680558Recruiting

Photopheresis in Early-stage Mycosis Fungoides

The purpose of this study is to determine whether photopheresis therapy can be used to improve the clinical course of early stage cutaneous T-cell lymphoma (CTCL). Currently, photopheresis is performe...

New York, NYPHASE274 participantsColumbia University

View Study Details

NCT06377566Recruiting

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

The purpose of this study is to test whether BV-AVD is an effective treatment in people with early stage, bulky Hodgkin lymphoma that was recently diagnosed and who have not yet received any treatment...

New York, NYPHASE271 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05010005Recruiting

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people wit...

New York, NYPHASE170 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07015242Recruiting

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central N...

New York, NYPHASE265 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT05533775Recruiting

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and et...

New York, NYPHASE165 participantsHoffmann-La Roche

View Study Details

NCT06854003Recruiting

BRAZAN Trial in Frontline MCL

This study aims to evaluate the efficacy and safety of an induction regimen combining Bendamustine, Rituximab, Cytarabine (AraC), and Zanubrutinib (BRAZAN), followed by maintenance therapy with Zanubr...

New York, NYPHASE260 participantsChristine Ryan

View Study Details

NCT07283822Recruiting

Amping up With PemJAK

The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas....

New York, NYPHASE253 participantsSeda S. Tolu

View Study Details

NCT06736613Recruiting

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

The purpose of this study is to find out how many people with B-cell lymphoma who are at high risk for central nervous system/CNS relapse test positive for cerebral spinal fluid/CSF ctDNA but test neg...

New York, NYPHASE250 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT04747236Recruiting

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

The purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma (PTCL). This study will ...

New York, NYPHASE250 participantsUniversity of Virginia

View Study Details

NCT06733441Recruiting

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma....

New York, NYPHASE150 participantsTreeline Biosciences, Inc.

View Study Details

NCT05940272Recruiting

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance...

New York, NYNA48 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT04234048Recruiting

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL)....

New York, NYPHASE146 participantsSciTech Development, Inc.

View Study Details

NCT06534060Recruiting

MB-105 in Patients With CD5 Positive T-cell Lymphoma

This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon tw...

New York, NYPHASE246 participantsMarch Biosciences Inc

View Study Details

NCT06563596Recruiting

Epco, Zanu, Ritux for R/R FL or MZL

The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma ...

New York, NYPHASE245 participantsReid Merryman, MD

View Study Details

NCT04626791Recruiting

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as first line...

New York, NYPHASE245 participantsAcademic and Community Cancer Research United

View Study Details

NCT06765317Recruiting

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

The researchers are doing this study to find out if the study treatment is an effective treatment that causes few or mild side effects in people with diffuse large B-cell lymphoma (DLBCL), high-grade ...

New York, NYPHASE242 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06693830Recruiting

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

The purpose of this study is to 1) determine whether it is feasible to measure circulating tumor DNA (ctDNA) in real-time during standard treatment for newly diagnosed diffuse large B-cell lymphoma (D...

New York, NYNA40 participantsHua-Jay J Cherng, MD

View Study Details

NCT04421560Recruiting

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The three drugs being used in the study are: ...

New York, NYPHASE137 participantsDana-Farber Cancer Institute

View Study Details

NCT06510361Recruiting

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a ty...

New York, NYPHASE235 participantsBeth Israel Deaconess Medical Center

View Study Details

NCT05934448Recruiting

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

This research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell lymphoma that has ...

New York, NYPHASE235 participantsJennifer Crombie, MD

View Study Details

NCT05272384Recruiting

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (re...

New York, NYPHASE132 participantsNational Cancer Institute (NCI)

View Study Details

NCT06420089Recruiting

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or refractory CD5 positive nodal T cell NHL. RP2D will b...

New York, NYPHASE130 participantsVittoria Biotherapeutics

View Study Details

NCT07001384Recruiting

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

The researchers are doing this study to see if alectinib in combination with duvelisib is a safe and effective time-limited treatment for people with relapsed or refractory ALK+ anaplastic large cell ...

New York, NYPHASE130 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05093335Recruiting

In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

The purpose of this study is to determine the uptake of the imaging agent \[68Ga\]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering mul...

New York, NYEARLY_PHASE130 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06175000Recruiting

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer ...

New York, NYPHASE228 participantsProvidence Health & Services

View Study Details

NCT07082868Recruiting

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

The purpose of this study is to find out whether the combination of epcoritamab and ibrutinib is a safe treatment approach that causes few or mild side effects in people with relapsed/refractory prima...

New York, NYPHASE126 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05996185Recruiting

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Single-arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) or CHOEP in patients with newly diagnosed or relapsed/refra...

New York, NYPHASE222 participantsYale University

View Study Details

NCT05077527Recruiting

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B...

New York, NYPHASE120 participantsAIDS Malignancy Consortium

View Study Details

NCT07249528Recruiting

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

The purpose of this study is to collect voice recordings and nervous system (neurologic) assessments from people with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) who are receiving standard tre...

New York, NY20 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05296304Recruiting

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides

The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF). Bexarotene is a form of ...

New York, NYPHASE120 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT03829540Recruiting

CD4CAR for CD4+ Leukemia and Lymphoma

This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell l...

New York, NYPHASE120 participantsHuda Salman

View Study Details

NCT04139304Recruiting

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

This feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (DA-EPOCH) works in tr...

New York, NYEARLY_PHASE115 participantsAIDS Malignancy Consortium

View Study Details

NCT07137494Recruiting

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

This study will test whether MB-CART19.1 is a safe and effective treatment for central nervous system lymphoma (CNSL). This study will test different doses of MB-CART19.1 to find the highest dose that...

New York, NYPHASE112 participantsMemorial Sloan Kettering Cancer Center

View Study Details

About Lymphoma Clinical Trials in New York

Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.

There are currently 67 lymphoma clinical trials recruiting participants in New York, NY. These studies are seeking a combined 9,740 participants. Research is being sponsored by University College, London, Regeneron Pharmaceuticals, Memorial Sloan Kettering Cancer Center and 36 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lymphoma Clinical Trials in New York — FAQ

Are there lymphoma clinical trials in New York?

Yes, there are 67 lymphoma clinical trials currently recruiting in New York, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New York?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.

Are clinical trials in New York free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.

What lymphoma treatments are being tested?

The 67 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.

Data updated July 16, 2026 from ClinicalTrials.gov